ArticleAntimicrobial agents and chemotherapy2019
Identification of a Carbapenemase-Producing Hypervirulent Klebsiella pneumoniae Isolate in the United States.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed.
- Genomic analyses identify nosocomial transmission of ST23 carbapenem-resistant hypervirulentVirulence · 2026Article
- ElevatedEmerging microbes & infections · 2026Article
- Comparative profiling of virulence determinants, capsular serotypes, and antimicrobial resistance in hypervirulent and classical Klebsiella pneumoniae isolates from liver abscess patients.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Clinical and genomic characteristics of hypervirulent Klebsiella pneumoniae isolated from throat culture suggesting an emerging causative agent of pharyngitis.BMC infectious diseases · 2026Article
- Carbapenem resistance and hypervirulence iniScience · 2026Review
- Carbapenemase-producing hypervirulentJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026Article
- The acquisition ofmBio · 2026Article
- Phenotypic characteristics and plasmid structure differences between ST11 carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- The epidemiology and clinical characteristics of carbapenem-resistantFrontiers in microbiology · 2026Article
- Article
- The acquisition ofbioRxiv : the preprint server for biology · 2025Article
- Coexistence of carbapenem resistance and hypervirulence in clinical Klebsiella pneumoniae isolates: a molecular and phenotypic analysis.BMC infectious diseases · 2025Article
- Phage Host Range Expansion Through Directed Evolution on Highly Phage-Resistant Strains ofInternational journal of molecular sciences · 2025Article
- New insights and perspectives on the virulence of hypervirulent Klebsiella pneumoniae.Folia microbiologica · 2025Review
- HypervirulentPharmaceuticals (Basel, Switzerland) · 2025Review
- De novo virulence feature discovery and risk assessment in Klebsiella pneumoniae based on microbial genome vectorization.Communications biology · 2025Article
- Carbapenem-Resistant, Virulence Plasmid-Harboring Klebsiella pneumoniae, United States.Emerging infectious diseases · 2025Article
- Phenotype and genotype of carbapenem-resistant hypervirulentJournal of medical microbiology · 2025Article
- Global emergence of Carbapenem-resistant Hypervirulent Klebsiella pneumoniae driven by an IncFIIEBioMedicine · 2025Article
- Prevalence and features of hypervirulentInfection and immunity · 2025Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report on a carbapenemase-producing hypervirulent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.